{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:36:16Z","timestamp":1793288176628,"version":"4.5.0"},"reference-count":62,"publisher":"American Society of Hematology","issue":"18","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,29]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Engineered T cells have transformed hemato-oncology, but chimeric antigen receptor (CAR) transgene-bearing T-cell malignancies have emerged as a rare and serious genomic safety signal after CAR T-cell therapy. Available data support a multistep model in which pre-existing clonal fitness, CAR T-cell manufacture, vector integration, construct biology, and postinfusion selection may contribute to different degrees. We review reported cases of CAR transgenic T-cell lymphoproliferative neoplasms and propose practical diagnostic criteria with a proportionate approach to genomic surveillance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2026033477","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:32:35Z","timestamp":1788348755000},"page":"2221-2228","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["CAR transgenic T-cell lymphoproliferative neoplasm: malignant transformation of cellular immunotherapy"],"prefix":"10.1182","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0768-1956","authenticated-orcid":false,"given":"Francis","family":"Baumgartner","sequence":"first","affiliation":[{"name":"1Pathology Department, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"},{"name":"2Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1492-5966","authenticated-orcid":false,"given":"Michael","family":"Dickinson","sequence":"additional","affiliation":[{"name":"1Pathology Department, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"},{"name":"2Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piers","family":"Blombery","sequence":"additional","affiliation":[{"name":"1Pathology Department, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"},{"name":"2Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia"},{"name":"3Collaborative Centre for Genomic Cancer Medicine, The University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2026102911213065300_bib1","unstructured":"U. S. Food and Drug Administration\n          . Approved Cellular and Gene Therapy Products. Accessed 5 January 2026. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products."},{"issue":"18","key":"2026102911213065300_bib2","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2408771","article-title":"Enhanced CAR T-cell therapy for lymphoma after previous failure","volume":"392","author":"Svoboda","year":"2025","journal-title":"N Engl J Med"},{"key":"2026102911213065300_bib3","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armored GPC3-CAR T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"issue":"2","key":"2026102911213065300_bib4","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ccell.2025.11.007","article-title":"IL-36\u03b3 armored CAR T cells reprogram neutrophils to induce endogenous antitumor immunity","volume":"44","author":"Zuo","year":"2026","journal-title":"Cancer Cell"},{"issue":"suppl 1","key":"2026102911213065300_bib5","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1182\/blood-2025-258","article-title":"A dual targeting BCMA and CD19 fastcar-t (GC012F\/AZD0120) as first-line therapy for newly diagnosed multiple myeloma [abstract]","volume":"146","author":"Du","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"2026102911213065300_bib6","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1182\/blood-2025-4145","article-title":"Tri-specific autologous CD19.20.22 chimeric antigen receptor (CAR) T-cells for patients with relapsed\/refractory B-cell lymphomas [abstract]","volume":"146","author":"Weeks","year":"2025","journal-title":"Blood"},{"issue":"suppl 2","key":"2026102911213065300_bib7","article-title":"Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti\u2013B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010 [abstract]","volume":"146","author":"Harrison","year":"2025","journal-title":"Blood"},{"issue":"8","key":"2026102911213065300_bib8","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41422-025-01128-1","article-title":"Allogeneic anti-CD19 CAR-T cells induce remission in refractory systemic lupus erythematosus","volume":"35","author":"Yang","year":"2025","journal-title":"Cell Res"},{"issue":"18","key":"2026102911213065300_bib9","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1016\/j.cell.2024.07.056","article-title":"Off-the-shelf CAR-T cells could prove paradigm shifting for autoimmune diseases","volume":"187","author":"Baker","year":"2024","journal-title":"Cell"},{"issue":"11","key":"2026102911213065300_bib10","doi-asserted-by":"crossref","first-page":"e833","DOI":"10.1016\/S2352-3026(22)00245-9","article-title":"UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial","volume":"9","author":"Benjamin","year":"2022","journal-title":"Lancet Haematol"},{"issue":"1","key":"2026102911213065300_bib11","doi-asserted-by":"crossref","first-page":"101437","DOI":"10.1016\/j.omtm.2025.101437","article-title":"Efficient nonviral integration of large transgenes into human T cells using Cas9-CLIPT","volume":"33","author":"Tommasi","year":"2025","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2026102911213065300_bib12","doi-asserted-by":"crossref","first-page":"1032397","DOI":"10.3389\/fimmu.2022.1032397","article-title":"Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-cell hematological malignancies","volume":"13","author":"Singh","year":"2022","journal-title":"Front Immunol"},{"issue":"7","key":"2026102911213065300_bib13","doi-asserted-by":"crossref","first-page":"e014873","DOI":"10.1136\/jitc-2026-014873","article-title":"Secondary peripheral T-cell lymphoma in a patient with DLBCL harboring BLM mutation following CD19\/CD22 bispecific CAR-T cell therapy","volume":"14","author":"Liu","year":"2026","journal-title":"J Immunother Cancer"},{"issue":"15","key":"2026102911213065300_bib14","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/bloodadvances.2019000219","article-title":"Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy","volume":"3","author":"Shah","year":"2019","journal-title":"Blood Adv"},{"issue":"7709","key":"2026102911213065300_bib15","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T-cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"issue":"22","key":"2026102911213065300_bib16","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa2401530","article-title":"Indolent CD4+ CAR T-cell lymphoma after cilta-cel CAR T-cell therapy","volume":"390","author":"Ozdemirli","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"2026102911213065300_bib17","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/s41591-025-03499-9","article-title":"Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody","volume":"31","author":"Braun","year":"2025","journal-title":"Nat Med"},{"issue":"7","key":"2026102911213065300_bib18","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJMoa2309728","article-title":"CAR+ T-cell lymphoma after cilta-cel therapy for relapsed or refractory myeloma","volume":"392","author":"Harrison","year":"2025","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2026102911213065300_bib19","doi-asserted-by":"crossref","first-page":"6939","DOI":"10.1182\/blood-2023-178806","article-title":"CAR+ T-cell lymphoma post ciltacabtagene autoleucel therapy for relapsed refractory multiple myeloma [abstract]","volume":"142","author":"Harrison","year":"2023","journal-title":"Blood"},{"issue":"6","key":"2026102911213065300_bib20","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJMoa2411507","article-title":"CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53","volume":"392","author":"Perica","year":"2025","journal-title":"N Engl J Med"},{"issue":"8","key":"2026102911213065300_bib21","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1056\/NEJMc2504588","article-title":"Targeted therapy of CAR+ T-cell lymphoma after anti-BCMA CAR T","volume":"393","author":"Aleman","year":"2025","journal-title":"N Engl J Med Overseas Ed"},{"issue":"12","key":"2026102911213065300_bib22","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.1016\/j.ymthe.2025.08.043","article-title":"Isolated oral CD30+\/CD4+ CAR+ T cell lymphoma in long-term remission after radiotherapy","volume":"33","author":"Bezerra","year":"2025","journal-title":"Mol Ther"},{"issue":"2","key":"2026102911213065300_bib23","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1016\/j.jtct.2023.12.228","article-title":"T-cell large granular lymphocyte population involving chimeric antigen receptor-modified T (CAR T) cells in patients with cytopenia after CD19-targeted CAR T-cell therapy: case series","volume":"30","author":"Albittar","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"13","key":"2026102911213065300_bib24","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa2402730","article-title":"Aggressive lymphoma after CD19 CAR T-cell therapy","volume":"391","author":"Kobbe","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"2026102911213065300_bib25","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/s41591-024-03458-w","article-title":"T cell malignancies after CAR T cell therapy in the DESCAR-T registry","volume":"31","author":"Dulery","year":"2025","journal-title":"Nat Med"},{"issue":"11","key":"2026102911213065300_bib26","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1182\/blood.2025031423","article-title":"Long-term follow-up of gastrointestinal CAR T-cell lymphoma: homing, clonal expansion, and response to cyclosporine","volume":"147","author":"Hosoya","year":"2026","journal-title":"Blood"},{"key":"2026102911213065300_bib27","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2026.300851","article-title":"Clonal expansion of CAR-T cells harboring lentivector integration in the PLAAT4 gene following anti-CD19 CAR T-cell therapy in a context of cutaneous T-cell lymphoma","author":"Guiraud","year":"11  2026","journal-title":"Haematologica"},{"issue":"16","key":"2026102911213065300_bib28","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood.2021010813","article-title":"Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells","volume":"138","author":"Bishop","year":"2021","journal-title":"Blood"},{"issue":"16","key":"2026102911213065300_bib29","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1182\/blood.2021010858","article-title":"Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells","volume":"138","author":"Micklethwaite","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2026102911213065300_bib30","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMp2400209","article-title":"Secondary cancers after chimeric antigen receptor T-cell therapy","volume":"390","author":"Verdun","year":"2024","journal-title":"N Engl J Med"},{"key":"2026102911213065300_bib31","unstructured":"BROAD Institue\n          . Carl June, Bruce Levine, Isabelle Rivi\u00e8re, and Michel Sadelain Receive The 2025 Merkin Prize at The Broad Institute for Chimeric Antigen Receptor (CAR) T-Cell Therapy. Accessed 16 December 2025. https:\/\/www.broadinstitute.org\/news\/carl-june-bruce-levine-isabelle-riviere-and-michel-sadelain-receive-2025-merkin-prize-broad."},{"issue":"4","key":"2026102911213065300_bib32","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/s41591-024-03478-6","article-title":"Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies","volume":"31","author":"Jadlowsky","year":"2025","journal-title":"Nat Med"},{"issue":"22","key":"2026102911213065300_bib33","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","article-title":"Risk of second malignancies and T-cell lymphoma after chimeric antigen receptor T-cell therapy","volume":"390","author":"Hamilton","year":"2024","journal-title":"N Engl J Med"},{"issue":"14","key":"2026102911213065300_bib34","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood.2022017094","article-title":"High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma","volume":"141","author":"Samur","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2026102911213065300_bib35","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41408-024-01167-8","article-title":"Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma","volume":"14","author":"Fortuna","year":"2024","journal-title":"Blood Cancer J"},{"issue":"13","key":"2026102911213065300_bib36","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1182\/bloodadvances.2025018853","article-title":"Diagnosis and management of immune effector cell-associated enterocolitis after ciltacabtagene autoleucel","volume":"10","author":"Lim","year":"2026","journal-title":"Blood Adv"},{"issue":"7951","key":"2026102911213065300_bib37","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41586-022-05692-z","article-title":"TET2 guards against unchecked BATF3-induced CAR T cell expansion","volume":"615","author":"Jain","year":"2023","journal-title":"Nature"},{"issue":"9","key":"2026102911213065300_bib38","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s41577-023-00843-3","article-title":"Clonal haematopoiesis and dysregulation of the immune system","volume":"23","author":"Belizaire","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2026102911213065300_bib39","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4049\/jimmunol.1700559","article-title":"The loss of TET2 promotes CD8+ T cell memory differentiation","volume":"200","author":"Carty","year":"2018","journal-title":"J Immunol"},{"issue":"620","key":"2026102911213065300_bib40","doi-asserted-by":"crossref","first-page":"eabh0272","DOI":"10.1126\/scitranslmed.abh0272","article-title":"Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity","volume":"13","author":"Prinzing","year":"2021","journal-title":"Sci Transl Med"},{"issue":"4","key":"2026102911213065300_bib41","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.3324\/haematol.2016.158428","article-title":"Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin","volume":"102","author":"Dobay","year":"2017","journal-title":"Haematologica"},{"issue":"7","key":"2026102911213065300_bib42","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","article-title":"Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters","volume":"120","author":"Lemonnier","year":"2012","journal-title":"Blood"},{"issue":"7313","key":"2026102911213065300_bib43","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nature09328","article-title":"Transfusion independence and HMGA2 activation after gene therapy of human \u03b2-thalassaemia","volume":"467","author":"Cavazzana-Calvo","year":"2010","journal-title":"Nature"},{"issue":"9","key":"2026102911213065300_bib44","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J Clin Invest"},{"key":"2026102911213065300_bib45","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ebiom.2018.07.008","article-title":"Integration mapping of piggyBac-mediated CD19 chimeric antigen receptor T cells analyzed by novel tagmentation-assisted PCR","volume":"34","author":"Hamada","year":"2018","journal-title":"eBioMedicine"},{"key":"2026102911213065300_bib46","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41586-025-09853-8","article-title":"An RNA splicing system that excises transposons from animal mRNAs","volume":"649","author":"Zhao","year":"2025","journal-title":"Nature"},{"issue":"9","key":"2026102911213065300_bib47","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1158\/1535-7163.MCT-17-1097","article-title":"Strategies to address chimeric antigen receptor tonic signalling","volume":"17","author":"Ajina","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2026102911213065300_bib48","doi-asserted-by":"crossref","first-page":"4732","DOI":"10.1038\/s41467-023-40303-z","article-title":"Complementarity-determining region clustering may cause CAR-T cell dysfunction","volume":"14","author":"Sar\u00e9n","year":"2023","journal-title":"Nat Commun"},{"issue":"625","key":"2026102911213065300_bib49","doi-asserted-by":"crossref","first-page":"eaay8248","DOI":"10.1126\/scisignal.aay8248","article-title":"4-1BB costimulation promotes CAR T cell survival through noncanonical NF-\u03baB signaling","volume":"13","author":"Philipson","year":"2020","journal-title":"Sci Signal"},{"issue":"6","key":"2026102911213065300_bib50","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"issue":"99","key":"2026102911213065300_bib51","doi-asserted-by":"crossref","first-page":"eadp3475","DOI":"10.1126\/sciimmunol.adp3475","article-title":"Subset-specific mitochondrial stress and DNA damage shape T cell responses to fever and inflammation","volume":"9","author":"Heintzman","year":"2024","journal-title":"Sci Immunol"},{"issue":"2","key":"2026102911213065300_bib52","doi-asserted-by":"crossref","first-page":"S487","DOI":"10.1016\/j.jtct.2024.02.009","article-title":"Absence of evidence for pervasive CAR19 driven T-cell lymphomagenesis revealed by comprehensive genomic profiling of an index tumor","volume":"30","author":"Hamilton","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"2026102911213065300_bib53","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s11684-023-1032-8","article-title":"EBV-associated lymphoproliferative disease post-CAR-T cell therapy","volume":"18","author":"Zhang","year":"2024","journal-title":"Front Med"},{"issue":"1","key":"2026102911213065300_bib54","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/ajcp\/aqaf020","article-title":"Epstein-Barr virus\u2013positive T- and NK-cell lymphoproliferative disorders: report from the 2023 SH\/EA4HP Lymphoma Workshop","volume":"164","author":"Quintanilla-Martinez","year":"2025","journal-title":"Am J Clin Pathol"},{"issue":"9","key":"2026102911213065300_bib55","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/bloodadvances.2023012019","article-title":"EBV+ nodal T\/NK-cell lymphoma associated with clonal hematopoiesis and structural variations of the viral genome","volume":"8","author":"Kato","year":"2024","journal-title":"Blood Adv"},{"issue":"5","key":"2026102911213065300_bib56","doi-asserted-by":"crossref","first-page":"636","DOI":"10.5966\/sctm.2013-0206","article-title":"Concise review: lessons learned from clinical trials of gene therapy in monogenic immunodeficiency diseases","volume":"3","author":"Williams","year":"2014","journal-title":"Stem Cells Transl Med"},{"issue":"14","key":"2026102911213065300_bib57","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa2405541","article-title":"Hematologic cancer after gene therapy for cerebral adrenoleukodystrophy","volume":"391","author":"Duncan","year":"2024","journal-title":"N Engl J Med"},{"issue":"18","key":"2026102911213065300_bib58","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N Engl J Med Overseas Ed"},{"issue":"22","key":"2026102911213065300_bib59","first-page":"2698","article-title":"Novel extragenic genomic safe harbors for precise therapeutic T-cell engineering","volume":"141","author":"Odak","year":"2023","journal-title":"Blood"},{"issue":"6753","key":"2026102911213065300_bib60","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"issue":"6","key":"2026102911213065300_bib61","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41408-021-00508-1","article-title":"AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia","volume":"11","author":"Nawaz","year":"2021","journal-title":"Blood Cancer J"},{"issue":"8110","key":"2026102911213065300_bib62","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41586-026-10235-x","article-title":"In vivo site-specific engineering to reprogram T cells","volume":"652","author":"Nyberg","year":"2026","journal-title":"Nature"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/18\/2221\/2596902\/blood_bld-2026-033477-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/18\/2221\/2596902\/blood_bld-2026-033477-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:21:45Z","timestamp":1793287305000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/18\/2221\/570682\/CAR-transgenic-T-cell-lymphoproliferative-neoplasm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,29]]},"references-count":62,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2026,10,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2026033477","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,29]]},"published":{"date-parts":[[2026,10,29]]}}}